Bio-Rad Launches a Measles, Mumps, Rubella, and Varicella-Zoster Virus IgG Kit for Its BioPlex 2200 System
May 24 2010 - 8:01AM
Marketwired
Bio-Rad Laboratories, Inc. (NYSE: BIO) and (NYSE: BIO.B), a
multinational manufacturer and distributor of life science research
and clinical diagnostic products, today announced the launch of the
BioPlex® 2200 MMRV IgG kit for use on the company's BioPlex® 2200
system. The MMRV IgG kit (measles; mumps; rubella; and the
varicella-zoster virus, which is commonly known as chicken pox)
provides simultaneous results for the four tests that are commonly
ordered together to determine a patient's susceptibility to MMRV.
The BioPlex 2200 MMRV IgG kit offers the advantage of
multiplexing to deliver test results from a single patient sample.
As a result, labs are able to generate test results quickly and
with less effort. MMRV are infectious diseases that are preventable
through vaccination. Maintaining high vaccination coverage and
providing MMRV IgG results when an individual's status is uncertain
is the most effective way to prevent disease outbreaks. Employees
in healthcare facilities and military personnel, among others, are
typically screened for MMRV IgG to ensure their safety.
"With the introduction of the BioPlex 2200 MMRV IgG kit, Bio-Rad
offers a compelling menu for infectious disease serology and
autoimmune testing laboratories," said John Goetz, Bio-Rad Vice
President and Group Manager Clinical Diagnostics. "The MMRV IgG kit
is the latest in our expanding menu of assays that run on our
BioPlex 2200 system."
The BioPlex 2200 system is the first and only fully-automated,
random access multiplex testing system and provides clinical
laboratories with the capability to rapidly process or "multiplex"
multiple individual tests that are traditionally processed
separately. The BioPlex 2200 system conserves patient sample
volume, consolidates workstations, and simplifies workflow.
About Bio-Rad Bio-Rad Laboratories, Inc.
(NYSE: BIO) and (NYSE: BIO.B) has remained at the center of
scientific discovery for more than 50 years, manufacturing and
distributing a broad range of products for the life science
research and clinical diagnostic markets. The company is renowned
worldwide among hospitals, universities, major research
institutions, as well as biotechnology and pharmaceutical companies
for its commitment to quality and customer service. Founded in
1952, Bio-Rad is headquartered in Hercules, California, and serves
more than 85,000 research and industry customers worldwide through
its global network of operations. The company employs over 6,800
people globally and had revenues of nearly $1.8 billion in 2009.
For more information, please visit www.bio-rad.com.
This release contains certain forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of 1995
and Section 21E of the Securities Exchange Act of 1934.
Forward-looking statements generally can be identified by the use
of forward-looking terminology such as, "believe," "expect," "may,"
"will," "intend," "estimate," "continue," or similar expressions or
the negative of those terms or expressions. Such statements involve
risks and uncertainties, which could cause actual results to vary
materially from those expressed in or indicated by the
forward-looking statements. For further information regarding the
Company's risks and uncertainties, please refer to the "Risk
Factors" in the Company's public reports filed with the Securities
and Exchange Commission, including the Company's most recent Annual
Report on Form 10-K, Quarterly Reports on Form 10-Q and Current
Reports on Form 8-K. The Company cautions you not to place undue
reliance on forward-looking statements, which reflect an analysis
only and speak only as of the date hereof. Bio-Rad Laboratories,
Inc., disclaims any obligation to update these forward-looking
statements.
For more information contact: Tina Cuccia Corporate
Communications Manager Bio-Rad Laboratories, Inc. 510-724-7000
Email Contact
Bio Rad Laboratories (NYSE:BIO)
Historical Stock Chart
From Apr 2024 to May 2024
Bio Rad Laboratories (NYSE:BIO)
Historical Stock Chart
From May 2023 to May 2024